To investigate if vaginal application of dequalinium chloride (DQC, Fluomizin) is as effective as vaginal clindamycin (CLM) in the treatment of bacterial vaginosis (BV). This was a multinational, multicenter, single-blind, randomized trial in 15 centers, including 321 women.
They were randomized to either vaginal DQC tablets or vaginal CLM cream. Follow-up visits were 1 week and 1 month after treatment.
Clinical cure based on Amseĺs criteria was the primary outcome. Secondary outcomes were rate of treatment failures and recurrences, incidence of post-treatment vulvovaginal candidosis (VVC), lactobacillary grade (LBG), total symptom score (TSC), and safety.